1. Home
  2. ENVX vs ORKA Comparison

ENVX vs ORKA Comparison

Compare ENVX & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enovix Corporation

ENVX

Enovix Corporation

HOLD

Current Price

$5.87

Market Cap

1.6B

Sector

Miscellaneous

ML Signal

HOLD

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

HOLD

Current Price

$32.18

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENVX
ORKA
Founded
2006
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ENVX
ORKA
Price
$5.87
$32.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
10
Target Price
$17.14
$52.70
AVG Volume (30 Days)
7.1M
454.9K
Earning Date
02-25-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$30,273,000.00
N/A
Revenue This Year
$36.03
N/A
Revenue Next Year
$102.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
45.98
N/A
52 Week Low
$5.27
$5.49
52 Week High
$16.49
$36.51

Technical Indicators

Market Signals
Indicator
ENVX
ORKA
Relative Strength Index (RSI) 36.27 54.14
Support Level $5.69 $31.00
Resistance Level $6.86 $33.89
Average True Range (ATR) 0.48 1.96
MACD -0.06 -0.28
Stochastic Oscillator 14.94 46.78

Price Performance

Historical Comparison
ENVX
ORKA

About ENVX Enovix Corporation

Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: